Michelle Zhang

Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy.

Bain Capital Public Equity LP is a SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded in 1996 as Brookside Capital LP. They are wholly-owned by Bain Capital LP, itself a subsidiary of Bain Capital Holdings LP. Bain Capital Public Equity provides investment advisory services to pooled investment vehicles (Public Equity Funds). Investors in the Public Equity Funds includes high net-worth individuals, banks, thrift institutions, pension and profit sharing plans, trusts, estates, charitable organizations, university endowments, corporations, limited partnerships and limited liability companies or other business entities.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Brookside Capital, Inc. is an independent wealth management firm headquartered in San Francisco, California. The firm was founded by James Rea in 1989. They provide investment management services to high-net worth individuals and charitable organizations.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Founded in 1992, Ziff Brothers Investments LLC is a hedge fund manager located in New York City. The firm is the primary investment vehicle of the Ziff family, founders of Ziff-Davis Publishing.

GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

BTG International Inc. (BTG International) is a venture capital subsidiary of BTG Ltd founded in 1981. The firm is headquartered in West Conshohocken, Pennsylvania.

FIAM LLC (do-business-as Fidelity Institutional Asset Management) is a SEC-registered investment advisor headquartered in Smithfield, Rhode Island. The firm was founded in 2006 and formerly known as Pyramis Global Advisors LLC. They are wholly-owned by FIAM Holdings LLC, which in turn is owned by FMR LLC, aka Fidelity Investments. FIAM provides discretionary investment management services to institutional accounts. They also sub-advice funds or accounts for affiliated advisers and unaffiliated advisers.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Part of Lundbeck Foundation, Lundbeck, Inc. is a pharmaceutical company that produces pharmaceutical preparations. The private company is based in Paramus, NJ. The company was founded by Jeffrey S. Aronin.

Part of Mabion SA, Biotech Consulting is a French company that provides business consulting services. The private company is based in Cornier, France.

Olivo Laboratories LLC provides solutions to skin-related medical problems through proprietary biomaterials technologies. Its platform technology consists of a tunable polysiloxane-based material that mimics youthful skin and can be engineered to provide a variety of targeted properties, including elasticity, breathability, invisibility, water resistance, protection. The company was founded by Robert S. Langer Jr. and Richard Rox Anderson and is headquartered in Cambridge, MA.

Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom.

Part of Ikena Oncology, Inc., Arrys Therapeutics, Inc. provides treatments to cancer patients. The private company is based in Boston, MA. The CEO of the company is Iain David Dukes.

Scorpion Therapeutics, Inc. provides health care services. The company is headquartered in Boston, MA.

Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation.

Gwynant Therapeutics develops new small molecules for oncology targets.

Trawsfynydd Therapeutics, Inc. engages in discovering and developing antiviral medicines. The company is located in the US.

Eilean Therapeutics LLC is a biopharmaceutical company based in Dover, DE. Eilean Therapeutics is focused on the discovery and development of first-in-class small molecule inhibitors that target escape mutations in hematologic and solid cancers. Eilean Therapeutics LLC is utilizing a proprietary hybrid AI platform to accelerate the execution of discovery and development of novel breakthrough medicines to maximize the clinical benefit when treating hematologic and solid malignancies. The company was founded in 2022 by John C. Byrd and is co-founded by OrbiMed, Torrey Pines Investment.